Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.21−0.00 (-1.83%)
Close on Nov 13, 2026Market cap $15.48MP/E –Yield –
Acumen Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Acumen Pharmaceuticals's cash was $78.60M at Sep 30, 2026. For fiscal 2025 it was $116.90M, down 32.0% from the year before. The highest annual figure on record is $243.76M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.90M | -32.0% |
| FY2024 | Dec 31, 2024 | $171.79M | -29.5% |
| FY2023 | Dec 31, 2023 | $243.76M | +37.2% |
| FY2022 | Dec 31, 2022 | $177.61M | -8.6% |
| FY2021 | Dec 31, 2021 | $194.24M | +343.7% |
| FY2020 | Dec 31, 2020 | $43.78M | +568.1% |
| FY2019 | Dec 31, 2019 | $6.55M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $78.60M | -38.0% |
| Q2 FY2026 | Jun 30, 2026 | $110.20M | -23.3% |
| Q1 FY2026 | Mar 31, 2026 | $128.40M | -14.0% |
| Q4 FY2025 | Dec 31, 2025 | $116.90M | -32.0% |
| Q3 FY2025 | Sep 30, 2025 | $126.84M | -36.8% |
| Q2 FY2025 | Jun 30, 2025 | $143.60M | -44.9% |
| Q1 FY2025 | Mar 31, 2025 | $149.38M | -40.9% |
| Q4 FY2024 | Dec 31, 2024 | $171.79M | -29.5% |
| Q3 FY2024 | Sep 30, 2024 | $200.58M | -7.0% |
| Q2 FY2024 | Jun 30, 2024 | $260.71M | +79.9% |
| Q1 FY2024 | Mar 31, 2024 | $252.75M | +80.0% |
| Q4 FY2023 | Dec 31, 2023 | $243.76M | +37.2% |
| Q3 FY2023 | Sep 30, 2023 | $215.62M | +7.7% |
| Q2 FY2023 | Jun 30, 2023 | $144.88M | -23.7% |
| Q1 FY2023 | Mar 31, 2023 | $140.41M | -25.7% |
| Q4 FY2022 | Dec 31, 2022 | $177.61M | -8.6% |
| Q3 FY2022 | Sep 30, 2022 | $200.19M | +0.1% |
| Q2 FY2022 | Jun 30, 2022 | $189.91M | +176.0% |
| Q1 FY2022 | Mar 31, 2022 | $189.09M | +356.7% |
| Q4 FY2021 | Dec 31, 2021 | $194.24M | +343.7% |
| Q3 FY2021 | Sep 30, 2021 | $199.96M | +10107.5% |
| Q2 FY2021 | Jun 30, 2021 | $68.81M | +2022.5% |
| Q1 FY2021 | Mar 31, 2021 | $41.41M | +532.0% |
| Q4 FY2020 | Dec 31, 2020 | $43.78M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.96M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.24M | – |
| Q4 FY2019 | Dec 31, 2019 | $6.55M | – |
See a number that looks wrong?